L21 ANSWER 1 OF 13 MEDLINE
AN 97156866 MEDLINE
DN 97156866 PubMed ID: 9003247
TI **Modulation** of the **alpha 2 macroglobulin receptor**/low density lipoprotein receptor related protein by interferon-gamma in human astroglial cells.
AU Businaro R; Fabrizi C; Persichini T; Starace G; Ennas M G; Fumagalli L; Lauro G M
CS Dipartimento di Scienze Cardiovascolari e Respiratorie, Universita La Sapienza, Rome, Italy.
SO JOURNAL OF NEUROIMMUNOLOGY, (1997 Jan) 72 (1) 75-81.
Journal code: 8109498. ISSN: 0165-5728.
CY Netherlands
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
OS GENBANK-X55077
EM 199702
ED Entered STN: 19970305
Last Updated on STN: 19970305
Entered Medline: 19970219

L21 ANSWER 2 OF 13 MEDLINE
AN 95072001 MEDLINE
DN 95072001 PubMed ID: 7526898
TI Presence of LDL receptor-related protein/**alpha 2-macroglobulin receptors** in macrophages of atherosclerotic lesions from cholesterol-fed New Zealand and heterozygous Watanabe heritable hyperlipidemic rabbits.
AU Daugherty A; Rateri D L
CS Cardiovascular Division, Washington University School of Medicine, St. Louis, MO 63110.
NC HL-17646 (NHLBI)
SO ARTERIOSCLEROSIS AND THROMBOSIS, (1994 Dec) 14 (12) 2017-24.
Journal code: 9101388. ISSN: 1049-8834.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199412
ED Entered STN: 19950116
Last Updated on STN: 19960129
Entered Medline: 19941230

L21 ANSWER 3 OF 13 MEDLINE
AN 94144688 MEDLINE
DN 94144688 PubMed ID: 7508685
TI Expression of **alpha 2-macroglobulin receptor**/low density lipoprotein receptor-related protein and the 39-kd receptor-associated protein in human trophoblasts.
AU Coukos G; Gafvels M E; Wisel S; Ruelaz E A; Strickland D K; Strauss J F 3rd; Coutifaris C
CS Department of Obstetrics and Gynecology, University of Pennsylvania School of Medicine, Philadelphia.
NC GM-42581 (NIGMS)
HD-29946 (NICHD)
SO AMERICAN JOURNAL OF PATHOLOGY, (1994 Feb) 144 (2) 383-92.
Journal code: 0370502. ISSN: 0002-9440.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 199403

ED Entered STN: 19940330
Last Updated on STN: 19960129
Entered Medline: 19940317

L21 ANSWER 4 OF 13 MEDLINE
AN 92366474 MEDLINE
DN 92366474 PubMed ID: 1502154
TI Low density lipoprotein receptor-related protein/**alpha 2 -macroglobulin receptor** is an hepatic receptor for tissue-type plasminogen activator.
AU Bu G; Williams S; Strickland D K; Schwartz A L
CS Edward Mallinckrodt Department of Pediatrics, Washington University School of Medicine, St. Louis, MO 63110.
NC HL08467 (NHLBI)
HL17646 (NHLBI)
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1992 Aug 15) 89 (16) 7427-31.
Journal code: 7505876. ISSN: 0027-8424.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199209
ED Entered STN: 19920925
Last Updated on STN: 19980206
Entered Medline: 19920915

L21 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2003 ACS
AN 1999:180032 CAPLUS
DN 131:13513
TI Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia?
AU Broxterman, H. J.; Sonneveld, P.; Pieters, R.; Lankelma, J.; Eekman, C. A.; Loonen, A. H.; Schoester, M.; Ossenkoppele, G. J.; Lowenberg, B.; Pinedo, H. M.; Schuurhuis, G. J.
CS Department of Medical Oncology, University Hospital Vrije Universiteit, Amsterdam, 1007 MB, Neth.
SO Leukemia (1999), 13(2), 258-265
CODEN: LEUKED; ISSN: 0887-6924
PB Stockton Press
DT Journal
LA English
RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 6 OF 13 CAPLUS COPYRIGHT 2003 ACS
AN 1997:188130 CAPLUS
DN 126:275326
TI Low density lipoprotein receptor-related protein **modulates** the expression of tissue-type plasminogen activator in human colon fibroblasts
AU Hardy, Medora M.; Feder, Joseph; Wolfe, Richard A.; Bu, Guojun
CS Dep. of Cell Culture and Biochemistry, Monsanto Co., St. Louis, MO, 63167, USA
SO Journal of Biological Chemistry (1997), 272(10), 6812-6817
CODEN: JBCHA3; ISSN: 0021-9258
PB American Society for Biochemistry and Molecular Biology
DT Journal
LA English

L21 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2003 ACS
AN 1997:82858 CAPLUS
DN 126:169578
TI The low-density lipoprotein receptor-related protein, a multifunctional apolipoprotein E receptor, **modulates** hippocampal neurite

development
AU Narita, Masaaki; Bu, Guojun; Holtzman, David M.; Schwartz, Alan L.
CS Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, 63110, USA
SO Journal of Neurochemistry (1997), 68(2), 587-595
CODEN: JONRA9; ISSN: 0022-3042
PB Lippincott-Raven
DT Journal
LA English

L21 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2003 ACS
AN 1996:717281 CAPLUS
DN 126:29495
TI Apolipoprotein E-containing high density lipoprotein promotes neurite outgrowth and is a ligand for the low density lipoprotein receptor-related protein
AU Fagan, Anne M.; Bu, Guojun; Sun, Yuling; Daugherty, Alan; Holtzman, David M.
CS Dep. Neurology, Washington Univ. School Medicine, St. Louis, MO, 63110, USA
SO Journal of Biological Chemistry (1996), 271(47), 30121-30125
CODEN: JBCHA3; ISSN: 0021-9258
PB American Society for Biochemistry and Molecular Biology
DT Journal
LA English

L21 ANSWER 9 OF 13 USPATFULL
AN 1999:141305 USPATFULL
TI Adjuvant for transcutaneous immunization
IN Glenn, Gregory M., Bethesda, MD, United States
Alving, Carl R., Bethesda, MD, United States
PA The United States of America as represented by the U.S. Army Medical Research & Material Command, Washington, DC, United States (U.S. government)
PI US 5980898 19991109
AI US 1997-896085 19970717 (8)
RLI Continuation-in-part of Ser. No. US 1996-749164, filed on 14 Nov 1996
DT Utility
FS Granted
LN.CNT 1988
INCL INCLM: 424/184.100
INCLS: 424/449.000; 424/450.000; 424/236.000; 424/240.100; 424/241.100; 424/275.100; 530/363.000; 530/403.000
NCL NCLM: 424/184.100
NCLS: 424/085.100; 424/240.100; 424/241.100; 424/275.100; 424/449.000; 424/450.000; 530/363.000; 530/403.000
IC [6]
ICM: A61K039-00
ICS: C07K014-005; C07K014-195
EXF 424/449; 424/450; 424/184.1; 424/236; 424/240.1; 424/241.1; 424/275.1; 530/363; 530/403
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L21 ANSWER 10 OF 13 USPATFULL
AN 1999:67356 USPATFULL
TI Parasitic helminth p22U proteins
IN Tripp, Cynthia Ann, Ft. Collins, CO, United States
Frank, Glenn Robert, Ft. Collins, CO, United States
Grieve, Robert B., Ft. Collins, CO, United States
PA Heska Corporation, Ft. Collins, CO, United States (U.S. corporation)
Colorado State University Research Foundation, Ft. Collins, CO, United States (U.S. corporation)
PI US 5912337 19990615
AI US 1995-460428 19950602 (8)

RLI Continuation of Ser. No. US 1993-109391, filed on 19 Aug 1993, now patented, Pat. No. US 5639876 which is a continuation-in-part of Ser. No. US 1993-3257, filed on 12 Jan 1993, now abandoned Ser. No. Ser. No. US 1993-3389, filed on 12 Jan 1993, now abandoned And Ser. No. US 1991-654226, filed on 12 Feb 1991, now abandoned , said Ser. No. US 3257 which is a continuation-in-part of Ser. No. US 654226 , said Ser. No. US 3389 which is a continuation-in-part of Ser. No. US 654226
DT Utility
FS Granted
LN.CNT 2357
INCL INCLM: 536/023.700
INCLS: 424/184.100; 424/185.100; 424/265.100; 530/350.000; 550/387.100
NCL NCLM: 536/023.700
NCLS: 424/184.100; 424/185.100; 424/265.100; 435/007.220; 530/350.000; 530/387.100
IC [6]
ICM: C07H021-04
ICS: A61K039-00
EXF 424/184.1; 424/185.1; 424/265.1; 530/350; 530/300; 550/380; 550/387.1; 550/388.2; 536/23.7
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L21 ANSWER 11 OF 13 USPATFULL
AN 1998:30893 USPATFULL
TI Non-mammalian DNA virus to express an exogenous gene in a mammalian cell
IN Boyce, Frederick M., Belmont, MA, United States
PA The General Hospital Corporation, Boston, MA, United States (U.S. corporation)
PI US 5731182 19980324
AI US 1995-486341 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1994-311157, filed on 23 Sep 1994
DT Utility
FS Granted
LN.CNT 1730
INCL INCLM: 435/183.000
INCLS: 435/320.100; 435/069.100; 435/070.100
NCL NCLM: 435/183.000
NCLS: 435/069.100; 435/070.100; 435/320.100
IC [6]
ICM: C12N009-00
ICS: C12N015-63; C12P021-02
EXF 435/183; 435/183T; 435/320.1; 435/69.1; 435/70.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L21 ANSWER 12 OF 13 USPATFULL
AN 97:104113 USPATFULL
TI Parasitic helminth p4 proteins
IN Tripp, Cynthia Ann, Ft. Collins, CO, United States
Frank, Glenn Robert, Ft. Collins, CO, United States
Grieve, Robert B., Ft. Collins, CO, United States
PA Heska Corporation, Ft. Collins, CO, United States (U.S. corporation)
Colorado State University Research Foundation, Ft. Collins, CO, United States (U.S. corporation)
PI US 5686080 19971111
AI US 1995-459019 19950602 (8)
RLI Continuation of Ser. No. US 1993-109391, filed on 19 Aug 1993, now patented, Pat. No. US 5639876 which is a continuation-in-part of Ser. No. US 1993-3257, filed on 12 Jan 1993, now abandoned Ser. No. Ser. No. US 1993-3389, filed on 12 Jan 1993, now abandoned And Ser. No. US 1991-654226, filed on 12 Feb 1991, now abandoned , said Ser. No. US -3257 And Ser. No. US -3389 , each Ser. No. US - which is a continuation-in-part of Ser. No. US -654226
DT Utility
FS Granted

LN.CNT 2279
INCL INCLM: 424/265.100
INCLS: 424/154.100; 424/185.100; 424/266.100; 530/350.000; 435/069.100; 435/069.300; 435/071.100
NCL NCLM: 424/265.100
NCLS: 424/184.100; 424/185.100; 424/266.100; 435/069.100; 435/069.300; 435/071.100; 530/350.000
IC [6]
ICM: A61K039-00
ICS: A61K039-002; A61K039-38; C07K014-00
EXF 530/350; 530/300; 424/265.1; 424/266.1; 424/184.1; 424/185.1; 435/69.1; 435/69.3; 435/71.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L21 ANSWER 13 OF 13 USPATFULL
AN 97:52122 USPATFULL
TI Nucleic acid molecules encoding novel parasitic helminth proteins
IN Tripp, Cynthia Ann, Ft. Collins, CO, United States
Frank, Glenn Robert, Ft. Collins, CO, United States
Grieve, Robert B., Ft. Collins, CO, United States
PA Heska Corporation, Ft. Collins, CO, United States (U.S. corporation)
Colorado State University Research Foundation, Ft. Collins, CO, United States (U.S. corporation)
PI US 5639876 19970617
AI US 1993-109391 19930819 (8)
RLI Continuation-in-part of Ser. No. US 1993-3257, filed on 12 Jan 1993, now abandoned Ser. No. Ser. No. US 1993-3389, filed on 12 Jan 1993, now abandoned And Ser. No. US 1991-654226, filed on 12 Feb 1991, now abandoned , said Ser. No. US -3257 And Ser. No. US -3389 , each Ser. No. US - which is a continuation-in-part of Ser. No. US -654226
DT Utility
FS Granted
LN.CNT 2327
INCL INCLM: 536/023.700
INCLS: 536/022.100; 536/023.100; 435/069.100; 435/069.300; 435/071.100; 424/184.100; 424/185.100; 424/265.100; 424/266.100
NCL NCLM: 536/023.700
NCLS: 424/184.100; 424/185.100; 424/265.100; 424/266.100; 435/069.100; 435/069.300; 435/071.100; 536/022.100; 536/023.100
IC [6]
ICM: C07H019-00
ICS: C07H021-04; C12P021-04; A61K039-00
EXF 536/27; 536/22.1; 536/23.1; 536/23.7; 424/265.1; 424/269.1; 424/184.1; 424/185.1; 424/165.1; 424/266.1; 435/69.1; 435/69.3; 435/71.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

☐ 1: FEBS Lett 1994 Nov 14;354(3):279-83

Very low density lipoprotein receptor from mammary gland and mammary epithelial cell lines binds and mediates endocytosis of M(r) 40,000 receptor associated protein.

Simonsen AC, Heegaard CW, Rasmussen LK, Ellgaard L, Kjoller L, Christensen A, Etzerodt M, Andreasen PA.

Department of Molecular Biology, University of Aarhus, Denmark.

We here report that the M(r) 40,000 receptor associated protein (RAP), previously found to bind to alpha 2-macroglobulin receptor/low density lipoprotein receptor related protein (alpha 2MR/LRP) and glycoprotein 330 (gp330), binds to an M(r) 105,000 membrane protein from bovine mammary gland, human mamma tumors and mammary epithelial cell lines. We have purified this protein from bovine and human sources. N-terminal amino acid sequencing and immunoblotting analyses showed that the protein was identical or closely related to very low density lipoprotein receptor (VLDL-R). Experiments with the human mamma carcinoma cell line MCF-7 showed that this receptor was able to mediate an efficient endocytosis of RAP. These novel findings strongly suggest that RAP functions as a modulator of ligand binding to VLDL-R, similarly to alpha 2MR/LRP and gp330.

PMID: 7957939 [PubMed - indexed for MEDLINE]

Display Abstract Sort Save Text Clip Add Order

A novel mechanism for controlling the activity of alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Multiple regulatory sites for 39-kDa receptor-associated protein.

Williams SE, Ashcom JD, Argraves WS, Strickland DK.

Biochemistry Laboratory, American Red Cross, Rockville, Maryland 20855.

The alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein (alpha 2MR/LRP) consists of two polypeptides, 515 and 85 kDa, that are noncovalently associated. A 39-kDa polypeptide, termed the receptor-associated protein (RAP), interacts with the 515-kDa subunit after biosynthesis of these molecules and remains associated on the cell surface. This molecule regulates ligand binding of alpha 2MR/LRP (Herz, J., Goldstein, J. L., Strickland, D. K., Ho, Y. K., and Brown, M. S. (1991) J. Biol. Chem. 266, 21232-21238). Titration and binding studies indicate that RAP binds to two equivalent binding sites on alpha 2MR/LRP, with a KD of 14 nM. Heterologous ligand displacement experiments demonstrated that RAP completely inhibits the binding of 125I-activated alpha 2M to human fibroblasts and to the purified alpha 2MR/LRP, with a Ki of 23 and 26 nM, respectively. A direct correlation between the degree of binding of RAP to the receptor and the degree of ligand inhibition was observed, indicating that as the RAP binding sites are saturated, alpha 2MR/LRP loses its ability to bind ligands. Thus, the amount of RAP bound to alpha 2MR/LRP dictates the level of receptor activity. A model is proposed in which alpha 2MR/LRP contains multiple ligand binding sites, each regulated by a separate RAP site.

PMID: 1374383 [PubMed - indexed for MEDLINE]

Display Abstract Sort Save Text Clip Add Order

☐ 1: Biochim Biophys Acta 1997 Mar 1;1355 (3):231-40

Nickel is a specific antagonist for the catabolism of activated alpha 2-macroglobulin.

Kancha RK, Hussain MM.

Department of Pathology, Allegheny University of the Health Sciences, Philadelphia, PA 19129, USA.

The multifunctional low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor (LRP) binds and degrades several ligands involved in protease and lipoprotein metabolism. We previously reported that nickel (Ni2+) specifically inhibits the binding of activated alpha 2-macroglobulin (alpha 2 M*) at 4 degrees C to LRP and had no effect on the binding of other ligands to the receptor (Hussain et al. (1995) Biochem. 34, 16074-16081). In the current investigation, we have examined the effect of Ni2+ on the catabolism of 125 I-labeled alpha 2M*, receptor-associated protein (RAP) and lactoferrin at physiologic temperatures by fibroblasts. Nickel completely inhibited the degradation of alpha 2M* over a wide range of concentrations (0.3-2.4 nM); 50% inhibition for the degradation of 1.2 nM alpha 2M* was observed at 0.5 mM Ni2+. Furthermore, nickel inhibited the binding, internalization and degradation of 125I-alpha 2M* in a dose- and time-dependent manner. In contrast, the degradation of several concentrations of 125I-RAP by fibroblasts was not affected by different amounts of Ni2+ for various times. Similarly, Ni2+ did not inhibit the degradation of lactoferrin either before or after treating the cells with heparitinase to remove cell-surface proteoglycans. The degradation of lactoferrin was, however, inhibited by the RAP indicating that lactoferrin degradation was mediated by the LRP. These data suggest that Ni2+ is a specific inhibitor for the degradation of alpha 2M*.

PMID: 9060994 [PubMed - indexed for MEDLINE]